A comparative study of Curcuma zedoaria and Zingiber zerumbet plantlet production using different micropropagation systems

Curcuma zedoaria and Zingiber zerumbet plantlets could be micropropagated via induction of multiple shoots from in vitro shoot explants using different culture systems such as the agar-gelled medium cultures, shake flask system and temporary immersion system (TIS). The immersion period in TIS did not influence shoot multiplication rates of both species. However, proliferation medium (MS plus 0.5mg/L BA and 0.5 mg/L IBA) supplemented with different sucrose concentration affected the production of multiple shoots but did not affect the fresh and dried shoot biomass for both species when using TIS. The TIS was able to eliminate hyperhydricity problem encountered when using the shake flask system. However, all the in vitro plantlets of both species produced by the three culture systems survived and grew normally with no morphological changes after acclimatization. This study indicated that TIS was the best choice of in vitro propagation technique for production of normal C. zedoaria and Z. zerumbet plantlets

Somatic embryogenesis and root regeneration in Hyoscyamus niger L. for the production of hyoscyamine

Embryogenic calli could be induced from the leaf, petiole and root pieces of Hyoscyamus niger using different induction medium. The embryogenic calli produced were different in term of colour and morphology. Small globular somatic embryos could only be produced from the leaf explants culturedon Murashige and Skoog (MS) medium supplemented with 6 mg/L picloram. The globular embryos increased in size and developed into torpedo, heart shape or bipolar embryos accompanied by root formation after cultured onto MS basal medium for one week then followed by two weeks of culture in the maturation medium (MS + 1.0 mg/L BA). More roots could be regenerated from the leaf-derived somatic embryos when they were transferred into liquid MS medium without any plant growth regulator. Our result indicated that the leaf-derived embryogenic callus induced on solid MS supplemented with 6.0 mg/L of picloram did not show the presence of hyoscyamine. However, the H. niger roots regenerated from the somatic embryos showed the presence of hyoscyamine. Although the somatic embryos failed to germinate to complete plantlets, the regenerated roots from the somatic embryos could be mass propagated to obtain hyoscyamine, the main tropane alkaloid produced in H. niger

Effect of yeast extract and chitosan on shoot proliferation, morphology and antioxidant activity of Curcuma mangga in vitro plantlets

This paper reported the effect of yeast extract and chitosan with combination of yeast extract on the growth and morphological changes and production of phenolics in the in vitro plantlets of Curcuma mangga. Yeast extract did not show any effect on the biomass and shoot proliferation of in vitro plantlets. However, the plantlets showed morphological abnormality when exposed to higher concentration of yeast extract (3.5 mgL-1 and above) supplemented into the culture medium. Plantlets cultured in media supplemented with 3.5 and 5.0 mgL-1 of yeast extract showed higher radical scavenging activity (RSA) which also indicated that stress induced by yeast extract might elicit the production of secondary metabolites which acted as free radical scavenger in 1,1-diphenyl-2- picrylhydrazyl (DPPH) assay. The plantlets treated with different concentration of chitosan combined with 3.5 mgL-1 of yeast extract affected the biomass of C. mangga. The plantlets that were cultured in media supplemented with 150 mgL-1 of chitosan combined and 3.5 mgL-1 of yeast extract showed higher RSA towards DPPH as compared to the other treatments. Kinetic of DPPH free RSA from C. mangga extract was considered slow as compared to quercetin and the correlation between total phenolic content and RSA was poor (R2 = 0.2293) for yeast extract and (R2 = 0.0373) for chitosan combination with yeast extract. This indicated that the presence of phenolic compounds in the extracts were not the major factor contributing to the anti-oxidative activity of C. mangga.Key words: Curcuma mangga, in-vitro, elicitor, phenolics, anti-oxidative activities

Examining mindfulness and its relation to self-differentiation and alexithymia

Published online first in 10 July 2013Research supports the association between mindfulness, emotion regulation, stress reduction, and interpersonal/relational wellness. The present study evaluated the potential effect of mindfulness on some indicators of psychological imbalance such as low self-differentiation and alexithymia. In this cross-sectional study, a sample of 168 undergraduates (72 % women) completed measures of perceived mindfulness (CAMS-R and PHLMS), self-differentiation (SIPI), and alexithymia (TAS-20). Results revealed positive correlations between the different dimensions of mindfulness and negative correlations between those dimensions, selfdifferentiation, and alexithymia. The dimensions of quality of mindfulness and acceptance were mediators in the relationship between self-differentiation and alexithymia. A nonsignificant interaction between gender and alexithymia was found. All mindfulness dimensions, but self-differentiation, contributed to explain the allocation of the non-alexithymic group. These results indicate that mindfulness seems to be a construct with great therapeutic and research potential at different levels, suggesting that some aspects of mindfulness seem to promote a better self-differentiation and prevent alexithymia

Disrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy

Data availability: The data supporting the conclusions of this paper are provided in the article and the Supplementary Information. Any remaining raw data will be available from the corresponding author upon reasonable request. Source Data are provided with this paper.Supplementary information is available online at https://www.nature.com/articles/s41467-021-24849-4#Sec23 .Source data are available online at https://www.nature.com/articles/s41467-021-24849-4#Sec24 .Mutations in the LaminA gene are a common cause of monogenic dilated cardiomyopathy. Here we show that mice with a cardiomyocyte-specific Lmna deletion develop cardiac failure and die within 3–4 weeks after inducing the mutation. When the same Lmna mutations are induced in mice genetically deficient in the LINC complex protein SUN1, life is extended to more than one year. Disruption of SUN1’s function is also accomplished by transducing and expressing a dominant-negative SUN1 miniprotein in Lmna deficient cardiomyocytes, using the cardiotrophic Adeno Associated Viral Vector 9. The SUN1 miniprotein disrupts binding between the endogenous LINC complex SUN and KASH domains, displacing the cardiomyocyte KASH complexes from the nuclear periphery, resulting in at least a fivefold extension in lifespan. Cardiomyocyte-specific expression of the SUN1 miniprotein prevents cardiomyopathy progression, potentially avoiding the necessity of developing a specific therapeutic tailored to treating each different LMNA cardiomyopathy-inducing mutation of which there are more than 450.This research was funded in part by the Singapore Biomedical Research Council Translational Clinical Research grant NMRC/TCR/006-NUHS/2013 to C.L.S. and R.S.Y.F., and the Singapore Agency for Science, Technology, and Research (A*STAR) to C.L.S

Rationalization and Design of the Complementarity Determining Region Sequences in an Antibody-Antigen Recognition Interface

Protein-protein interactions are critical determinants in biological systems. Engineered proteins binding to specific areas on protein surfaces could lead to therapeutics or diagnostics for treating diseases in humans. But designing epitope-specific protein-protein interactions with computational atomistic interaction free energy remains a difficult challenge. Here we show that, with the antibody-VEGF (vascular endothelial growth factor) interaction as a model system, the experimentally observed amino acid preferences in the antibody-antigen interface can be rationalized with 3-dimensional distributions of interacting atoms derived from the database of protein structures. Machine learning models established on the rationalization can be generalized to design amino acid preferences in antibody-antigen interfaces, for which the experimental validations are tractable with current high throughput synthetic antibody display technologies. Leave-one-out cross validation on the benchmark system yielded the accuracy, precision, recall (sensitivity) and specificity of the overall binary predictions to be 0.69, 0.45, 0.63, and 0.71 respectively, and the overall Matthews correlation coefficient of the 20 amino acid types in the 24 interface CDR positions was 0.312. The structure-based computational antibody design methodology was further tested with other antibodies binding to VEGF. The results indicate that the methodology could provide alternatives to the current antibody technologies based on animal immune systems in engineering therapeutic and diagnostic antibodies against predetermined antigen epitopes

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

BACKGROUND: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival. METHODS: We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0–2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m2 intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544). FINDINGS: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86–107) in the abiraterone trial and 72 months (61–74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8–86·9) in the abiraterone group versus 45·7 months (41·6–52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53–0·73]; p<0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9–81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3–59·0) in the standard of care group (HR 0·65 [0·55–0·77]; p<0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83–1·32]; pinteraction=0·71) or between-trial heterogeneity (I2 p=0·70). In the first 5 years of treatment, grade 3–5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (<1%) with standard of care in the abiraterone trial). INTERPRETATION: Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years. FUNDING: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas